Eyenovia Inc
NASDAQ:EYEN
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.5080
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.4920/ 2
  • Ask / Lots
    0.5389/ 3
  • Open / Previous Close
    --- / 0.5080
  • Day Range
    ---
  • 52 Week Range
    0.3700
    2.5700
  • Volume
    1,263

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Oct 16, 2024

  • Oct 1, 2024

  • Sep 27, 2024

      Show headlines and story abstract

    • 8:58AM ET on Friday Sep 27, 2024 by MT Newswires
      Companies Mentioned: EYEN
      08:58 AM EDT, 09/27/2024 (MT Newswires) -- Eyenovia (EYEN) said Friday it signed an agreement for a $4 million registered direct offering with a healthcare institutional investor. Eyenovia said it will offer about 8.7 million shares and warrants to ...

    • 8:30AM ET on Friday Sep 27, 2024 by Dow Jones
      Companies Mentioned: EYEN

      Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

      NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the treatment of pediatric progressive myopia, today announced it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 8,695,653 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 8,695,653 shares of common stock in a registered direct offering at a combined offering price of $0.46 per share and accompanying warrant. The warrants have an exercise price of $0.50 per share, will be exercisable commencing six months from the date of issuance and will expire five years from the initial exercise date. The closing of the offering is expected to take place on or about September 30, 2024, subject to the satisfaction of customary closing conditions.

    • 8:30AM ET on Friday Sep 27, 2024 by Dow Jones
      Companies Mentioned: EYEN

      Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

      NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the treatment of pediatric progressive myopia, today announced it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 8,695,653 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 8,695,653 shares of common stock in a registered direct offering at a combined offering price of $0.46 per share and accompanying warrant. The warrants have an exercise price of $0.50 per share, will be exercisable commencing six months from the date of issuance and will expire five years from the initial exercise date. The closing of the offering is expected to take place on or about September 30, 2024, subject to the satisfaction of customary closing conditions.

Peers Headlines